Condition
Relapsed and Refractory Multiple Myeloma (RRMM)
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Early P 1 (1)
Trial Status
Active Not Recruiting1
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07234721Early Phase 1Not Yet RecruitingPrimary
SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
NCT06479954Active Not RecruitingPrimary
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
NCT05673967CompletedPrimary
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Showing all 3 trials